Analysis of potential antiviral resistance mutation profiles within the HBV reverse transcriptase in untreated chronic hepatitis B patients using an ultra-deep pyrosequencing method.

[1]  Tommy F. Liu,et al.  Low-Level Persistence of Drug Resistance Mutations in Hepatitis B Virus-Infected Subjects with a Past History of Lamivudine Treatment , 2012, Antimicrobial Agents and Chemotherapy.

[2]  Xueen Liu,et al.  Discrepancy of potential antiviral resistance mutation profiles within the HBV reverse transcriptase between nucleos(t)ide analogue‐untreated and ‐treated patients with chronic hepatitis B in a hospital in China , 2012, Journal of medical virology.

[3]  C. Perno,et al.  Characterization of drug-resistance mutations in HBV D-genotype chronically infected patients, naïve to antiviral drugs. , 2011, Antiviral research.

[4]  A. Alberti,et al.  741 GENOTYPE-SPECIFIC MUTATIONS IN THE RT REGION OF HBV POLYMERASE POTENTIALLY ASSOCIATED TO DEVELOPMENT AND EVOLUTION OF RESISTANCE TO ORAL ANTIVIRAL THERAPY , 2011 .

[5]  Susan P. Holmes,et al.  A classification model for G-to-A hypermutation in hepatitis B virus ultra-deep pyrosequencing reads , 2010, Bioinform..

[6]  H. Zhuang,et al.  Characterization of potential antiviral resistance mutations in hepatitis B virus reverse transcriptase sequences in treatment-naïve Chinese patients. , 2010, Antiviral research.

[7]  Zhao Su-ling.  Analysis of the reverse transcriptase domain of HBV polymerase in 310 patients with chronic hepatitis B under Lamivudine therapy , 2010 .

[8]  T. Luedde,et al.  Prevalence, viral replication efficiency and antiviral drug susceptibility of rtQ215 polymerase mutations within the hepatitis B virus genome. , 2009, Journal of hepatology.

[9]  Aijaz Ahmed,et al.  Ultra-deep pyrosequencing of hepatitis B virus quasispecies from nucleoside and nucleotide reverse-transcriptase inhibitor (NRTI)-treated patients and NRTI-naive patients. , 2009, The Journal of infectious diseases.

[10]  R. Takkenberg,et al.  Susceptibility of hepatitis B virus to lamivudine restored by resistance to adefovir , 2009, Journal of medical virology.

[11]  G. Raimondo,et al.  Variability of reverse transcriptase and overlapping S gene in hepatitis B virus isolates from untreated and lamivudine-resistant chronic hepatitis B patients , 2008, Antiviral therapy.

[12]  Samuel E. Fox,et al.  Applications of ultra-high-throughput sequencing. , 2009, Methods in molecular biology.

[13]  C. Mazzucco,et al.  Comprehensive evaluation of hepatitis B virus reverse transcriptase substitutions associated with entecavir resistance , 2008, Hepatology.

[14]  Huy A. Nguyen,et al.  S2075 Prevalence of HBV DNA Polymerase (B-DNA Pol) Mutations in 345 Patients with Treatment-NaïVe Chronic Hepatitis B (CHB) , 2008 .

[15]  V. Soriano,et al.  Hepatitis B virus escape mutants induced by antiviral therapy. , 2008, The Journal of antimicrobial chemotherapy.

[16]  S. Locarnini.  Primary resistance, multidrug resistance, and cross-resistance pathways in HBV as a consequence of treatment failure , 2008, Hepatology international.

[17]  Y. Paik,et al.  563 HEPATITIS B VIRUS QUASISPECIES IN THE POLYMERASE GENE IN TREATMENT-NAIVE CHRONIC HEPATITIS B PATIENTS , 2008 .

[18]  V. Soriano,et al.  Selection of Hepatitis B Virus (HBV) Vaccine Escape Mutants in HBV-Infected and HBV/HIV-Coinfected Patients Failing Antiretroviral Drugs With Anti-HBV Activity , 2007, Journal of acquired immune deficiency syndromes.

[19]  K. Borroto-Esoda,et al.  Pooled analysis of amino acid changes in the HBV polymerase in patients from four major adefovir dipivoxil clinical trials. , 2007, Journal of hepatology.

[20]  Angeline Bartholomeusz,et al.  Antiviral drug‐resistant HBV: Standardization of nomenclature and assays and recommendations for management , 2007, Hepatology.

[21]  B. Rodés,et al.  Mutations affecting the replication capacity of the hepatitis B virus , 2006, Journal of viral hepatitis.

[22]  Angeline Bartholomeusz,et al.  HBV drug resistance: mechanisms, detection and interpretation. , 2006, Journal of hepatology.

[23]  Dr. Chau Tai-Nin,et al.  Hepatocellular Carcinoma and Hepatitis B Virus , 2006 .

[24]  F. Zoulim.  Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic hepatitis B virus infection. , 2004, Antiviral research.

[25]  B. Tehan,et al.  Comparisons of the Hbv and HIV Polymerase, and Antiviral Resistance Mutations , 2003, Antiviral therapy.

[26]  Antonina Smedile,et al.  Identification of HBV DNA sequences that are predictive of response to lamivudine therapy , 2004, Hepatology.

[27]  C. Osiowy,et al.  Evaluation of the INNO-LiPA HBV Genotyping Assay for Determination of Hepatitis B Virus Genotype , 2003, Journal of Clinical Microbiology.

[28]  Angeline Bartholomeusz,et al.  Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. , 2003, Gastroenterology.

[29]  M. Wulfsohn,et al.  Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. , 2003, The New England journal of medicine.

[30]  H. Van Vlierberghe,et al.  Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. , 2002, Gastroenterology.

[31]  S. Hasnain,et al.  Prevalence and profile of mutations associated with lamivudine therapy in Indian patients with chronic hepatitis B in the surface and polymerase genes of hepatitis B virus , 2002, Journal of medical virology.

[32]  H. Margolis,et al.  Genetic variation of hepatitis B surface antigen coding region among infants with chronic hepatitis B virus infection , 2002, Journal of medical virology.

[33]  D. Jackson,et al.  Reduced antigenicity of the hepatitis B virus HBsAg protein arising as a consequence of sequence changes in the overlapping polymerase gene that are selected by lamivudine therapy. , 2002, Virology.

[34]  D. Richman,et al.  Nomenclature for antiviral‐resistant human hepatitis B virus mutations in the polymerase region , 2001, Hepatology.

[35]  N. Enomoto,et al.  Prevalence and significance of naturally occurring mutations in the surface and polymerase genes of hepatitis B virus. , 1999, The Journal of infectious diseases.

[36]  F. Zoulim,et al.  Transient selection of a hepatitis B virus polymerase gene mutant associated with a decreased replication capacity and famciclovir resistance , 1999, Hepatology.

[37]  Y. Cheng,et al.  Role of additional mutations outside the YMDD motif of hepatitis B virus polymerase in L(-)SddC (3TC) resistance. , 1998, Biochemical pharmacology.

[38]  Lu-Yu Hwang,et al.  HEPATOCELLULAR CARCINOMA AND HEPATITIS B VIRUS A Prospective Study of 22 707 Men in Taiwan , 1981, The Lancet.